Healthcare Research Analysts

Donald Hooker is a Director, Equity Research Analyst with KeyBanc Capital Markets Inc. With the Company since 2013, his research coverage is focused on healthcare IT, biopharmaceutical services and laboratories.

Prior to joining KeyBanc Capital Markets, Hooker worked at Morgan Stanley as a research analyst covering the healthcare information (HCIT) sector. Previous equity research experience includes working as a healthcare services, IT and facilities analyst for UBS Securities.

Hooker graduated from the College of Wooster with a Bachelor of Arts in Economics. He is a Chartered Financial Analyst and holds the Series 7, 63, 86 and 87 industry licenses. Hooker is also a member of the CFA Institute and the New York Society of Security Analysts (NYSSA).

In its June 2017 Analyst Awards, Thomson Reuters StarMine recognized Hooker as the #1 earnings estimator in the Life Sciences Tools & Services sector. This was Hooker’s third StarMine award. In 2008, Hooker was recognized by The Wall Street Journal’s “Best on the Street” survey in the HCIT category.

Paul Knight is a Managing Director, Equity Research Analyst with KeyBanc Capital Markets Inc. His research coverage focuses on Healthcare, specifically the Life Science Technology, Bioproduction & Diagnostics sectors.

Prior to joining KeyBanc Capital Markets in fall 2020, Knight spent seven years as an Equity Research Analyst covering Life Science Technology at Janney, Montgomery & Scott in New York. Before that, he covered Life Science Technology for CLSA (Credit Agricole Securities) for three years. Previous professional experience includes being a founding partner and analyst at Thomas Weisel Partners Group (Stifel Financial), a senior analyst at Salomon Brothers, as well as a political analyst for NatWest Securities in New York and Washington, D.C., covering FDA and Congressional Committee meetings.

Knight earned an M.B.A. in Finance from George Washington University in Washington, D.C., and a B.S. in Economics from the University of Nebraska. He is a Chartered Financial Analyst, and also holds the Series 7, 62, 86 & 87 industry licenses.

Knight has been ranked as a top research analyst multiple times by surveys including Institutional Investor, Greenwich Associates, and The Wall Street Journal. He has delivered keynote addresses for several significant industry events, such as the Analytical & Life Sciences and Industry Association CEO Roundtable and the American Chemical Society’s annual meeting.

Matthew Mishan is a Vice President, Equity Research Analyst with KeyBanc Capital Markets Inc. His research coverage is focused on medical products companies.

Prior to his promotion to senior analyst, Mishan worked in Equity Research Product Management. Before that, he was a Research Associate on the automotive team for several years. Previous professional experience includes various roles in the financial services industry in Miami.

Mishan earned a Bachelor of Science in Business Administration degree in Finance and Management from the University of Florida in Gainesville, as well as a Master of Business Administration degree in Finance and Capital Markets from the Goizueta Business School at Emory University in Atlanta.